<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02483351</url>
  </required_header>
  <id_info>
    <org_study_id>20150433-01H</org_study_id>
    <nct_id>NCT02483351</nct_id>
  </id_info>
  <brief_title>Aneurysmal Subarachnoid Hemorrhage: Red Blood Cell Transfusion and Outcome</brief_title>
  <acronym>SAHaRA Pilot</acronym>
  <official_title>Aneurysmal Subarachnoid Hemorrhage: Red Blood Cell Transfusion and Outcome - A Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility of conducting a large trial
      examining the effect on clinical outcome of a liberal red blood cell (RBC) transfusion
      strategy compared to a restrictive strategy (usual care) in patients with aneurysmal
      subarachnoid hemorrhage (SAH).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Randomization Rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Liberal RBC Transfusion Strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Restrictive RBC Transfusion Strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Liberal Red Blood Cell Transfusion Strategy</intervention_name>
    <description>RBC Transfusion strategy with hemoglobin trigger of 100g/L</description>
    <arm_group_label>Liberal RBC Transfusion Strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Restrictive Red Blood Cell Transfusion Strategy</intervention_name>
    <description>Optional RBC Transfusion with hemoglobin trigger of &lt;=80g/L</description>
    <arm_group_label>Restrictive RBC Transfusion Strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years old at time of presentation

          2. First ever episode aneurysmal SAH

          3. Confirmed aneurysmal SAH diagnosis: as confirmed by treating Neurosurgeon or
             Neuro-interventionalist and supported by blood in subarachnoid space (demonstrated on
             cranial imaging or cerebrospinal fluid positive for xanthochromia) that is the result
             of a ruptured saccular aneurysm (confirmed by cranial imaging - cranial topography or
             magnetic resonance imaging angiography or catheter angiogram)

          4. Incident hemoglobin ≤100g/L within 14 days following SAH (defined by first day of
             hospital presentation)

        Exclusion Criteria:

          1. Physician and or family decision to withdraw/withhold critical care at time of
             enrolment

          2. Active bleeding with hemodynamic instability at time of enrolment

          3. Patients with contra-indication or known objection to blood transfusions

          4. SAH due to causes other than saccular aneurysm rupture including mycotic, traumatic
             and dissecting aneurysms, and aneurysms associated with arteriovenous malformations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shane English, MD MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lauralyn McIntyre, MD MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shane English</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2015</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ottawa Hospital Research Institute</investigator_affiliation>
    <investigator_full_name>Shane English</investigator_full_name>
    <investigator_title>Associate Scientist</investigator_title>
  </responsible_party>
  <keyword>Blood Transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

